Autophagy Types in Neurodegeneration
Introduction
The autophagy-lysosomal pathway encompasses three distinct mechanisms for intracellular degradation: macroautophagy, microautophagy, and chaperone-mediated autophagy (CMA). Each pathway utilizes different cellular machinery and serves specialized functions in maintaining proteostasis within neurons. Dysfunction in these pathways contributes significantly to the pathogenesis of Alzheimer's Disease (AD), Parkinson's Disease (PD), and other neurodegenerative disorders. [@nixon2013]
This page provides a detailed comparison of the three autophagy types, their molecular mechanisms, and their specific roles in neurodegeneration. Understanding the distinct contributions of each pathway is essential for developing targeted therapeutic interventions. [@bove2015]
Overview of Autophagy Types
| Feature | Macroautophagy | Microautophagy | CMA | [@nixon2019]
|---------|---------------|----------------|-----| [@pickrell2015]
| Cargo capture | Double-membrane autophagosome | Direct lysosomal invagination | Direct translocation across lysosomal membrane | [@du2016]
| Selectivity | Can be selective or bulk | Primarily bulk | Highly selective | [@bose2011]
| Key proteins | ATG proteins, LC3, p62 | LAMP2A, HSP90 | LAMP2A, HSC70 | [@bilsland2010]
| Membrane source | ER, Golgi, plasma membrane | Lysosomal membrane | Lysosomal membrane | [@martin2015]
| Size constraint | Large cargo (organelles, aggregates) | Small molecules | Single proteins only | [@li2012]
| Energy requirement | ATP-dependent | ATP-dependent | ATP-dependent | [@sahu2011]
| Neuronal relevance | Aggregate clearance, mitophagy | Basal turnover | Stress-induced, selective substrate | [@mizushima2014]
Macroautophagy
Molecular Mechanism
Macroautophagy is the most extensively studied form of autophagy, characterized by the formation of a double-membraned autophagosome that engulfs cytoplasmic cargo before fusing with the lysosome [1](https://pubmed.ncbi.nlm.nih.gov/22078879/). [@nishino2011]
Initiation: The process begins with the ULK1 complex (ULK1-ATG13-FIP200-ATG101) under the control of mTORC1 and AMPK. Under nutrient-rich conditions, mTORC1 phosphorylates and inhibits ULK1. During starvation or stress, AMPK activates ULK1 by direct phosphorylation, and mTORC1 inhibition is relieved [2](https://pubmed.ncbi.nlm.nih.gov/21465661/). [@rothenberg2012]
The ULK1 complex serves as the bridge between nutrient sensing and autophagy initiation. AMPK activates ULK1 through phosphorylation at multiple sites, including Ser317 and Ser777, while mTORC1 inhibits ULK1 via Ser757 phosphorylation [3](https://pubmed.ncbi.nlm.nih.gov/24270826/). [@cuervo1996]
Nucleation: The Class III PI3K complex (Vps34-Beclin1-VPS15-ATG14L) generates phosphatidylinositol 3-phosphate (PtdIns3P) at the phagophore assembly site. This marks the initial isolation membrane formation [4](https://pubmed.ncbi.nlm.nih.gov/20083227/). [@kiffin2010]
VPS34 is the catalytic subunit that produces PI(3)P, which is essential for recruiting proteins containing FYVE or PX domains to the nascent autophagosome. Beclin-1 serves as a platform protein that interacts with multiple regulators, including BCL-2 (which inhibits Beclin-1 under nutrient-rich conditions) and ATG14L (which targets the complex to the phagophore assembly site) [5](https://pubmed.ncbi.nlm.nih.gov/22949840/). [@martinezvicente2007]
Expansion: Two ubiquitin-like conjugation systems drive autophagosome expansion: [@koga2011]
- LC3 lipidation: LC3 is cleaved by ATG4, then conjugated to phosphatidylethanolamine (PE) via ATG7 (E1) and ATG3 (E2). The lipidated LC3-PE localizes to both inner and outer autophagosome membranes, serving as a marker for autophagy and facilitating cargo recruitment [6](https://pubmed.ncbi.nlm.nih.gov/23602568/).
- ATG12-ATG5 conjugation: ATG12 is activated by ATG7 and conjugated to ATG5, forming a complex with ATG16L that acts as an E3 ligase for LC3. This complex is essential for autophagosome expansion but dissociates upon completion [7](https://pubmed.ncbi.nlm.nih.gov/12665528/).
Closure: The expanding phagophore closes to form a complete double-membrane autophagosome containing engulfed cargo [8](https://pubmed.ncbi.nlm.nih.gov/18246591/). [@xilouri2013]
Fusion: The autophagosome fuses with the lysosome via SNARE proteins (STX17, SNAP-29, VAMP8) and LAMP proteins, forming an autolysosome where cargo is degraded by lysosomal hydrolases [9](https://pubmed.ncbi.nlm.nih.gov/23445837/). [@catz2012]
The fusion process requires the HOPS (homotypic vacuole fusion and protein sorting) tethering complex, which interacts with the SNARE machinery to promote membrane merger. LAMP1 and LAMP2 provide structural support for the lysosomal membrane and participate in autophagosome-lysosome fusion [10](https://pubmed.ncbi.nlm.nih.gov/25855379/). [@xilouri2011]
Role in Neurodegeneration
Macroautophagy is essential for neuronal health due to the post-mitotic nature of neurons, which cannot dilute damaged components through cell division [11](https://pubmed.ncbi.nlm.nih.gov/23921753/). [@deng2011]
Alzheimer's Disease: [@cuervo2014]
- Aβ accumulation inhibits autophagosome-lysosome fusion
- mTOR hyperactivation reduces autophagosome formation
- Tau aggregates interfere with lysosomal function
- Beclin-1 deficiency impairs autophagosome nucleation
- ATG5 and ATG12 expression reduced in AD brains [12](https://pubmed.ncbi.nlm.nih.gov/28793252/)
Neurons in AD show massive accumulation of autophagic vacuoles within dystrophic neurites, reflecting impaired completion of the autophagy-lysosomal pathway rather than increased autophagosome formation [13](https://pubmed.ncbi.nlm.nih.gov/19151615/).
Parkinson's Disease:
- LRRK2 mutations impair lysosomal function
- GBA1 mutations reduce glucocerebrosidase activity, affecting lysosomal homeostasis
- α-synuclein aggregates are poorly degraded by macroautophagy
- PINK1/Parkin mutations disrupt mitophagy [14](https://pubmed.ncbi.nlm.nih.gov/25611506/)
The selective autophagy receptor p62/SQSTM1, which is crucial for degrading ubiquitinated protein aggregates, shows altered distribution and function in PD brains. p62-positive inclusions are found in some PD models, indicating attempted but failed autophagy [15](https://pubmed.ncbi.nlm.nih.gov/26577373/).
Amyotrophic Lateral Sclerosis:
- TDP-43 aggregation disrupts autophagic flux
- C9orf72 mutations impair autophagy initiation
- Mutant SOD1 interferes with autophagosome formation
- Axonal transport defects prevent autophagosome-lysosome fusion [16](https://pubmed.ncbi.nlm.nih.gov/21638167/)
Motor neurons are particularly dependent on efficient macroautophagy due to their large size and the need to clear aggregates that form in distal axons. Disruption of axonal transport in ALS prevents autophagosomes from reaching lysosomes in the cell body [17](https://pubmed.ncbi.nlm.nih.gov/24356310/).
Huntington's Disease:
- Mutant huntingtin impairs selective autophagy
- Cargo recognition defects prevent proper aggregate clearance
- Autophagosomes form but fail to recognize ubiquitinated cargo [18](https://pubmed.ncbi.nlm.nih.gov/25449132/)
Therapeutic Targeting
| Target | Strategy | Agent | Status |
|--------|----------|-------|--------|
| mTORC1 | Inhibition | Rapamycin, everolimus | Approved for other uses |
| ULK1 | Activation | AICAR, metformin | Preclinical |
| ATG proteins | Gene therapy | AAV-ATG expression | Preclinical |
| TFEB | Activation | Trehalose, AAV-TFEB | Preclinical |
| VPS34 | Activation | VPS34-IN1 | Preclinical |
Microautophagy
Molecular Mechanism
Microautophagy involves the direct engulfment of cytoplasm by the lysosomal membrane through invagination, protrusion, or septation [19](https://pubmed.ncbi.nlm.nih.gov/22783373/). Unlike macroautophagy, it does not require the formation of double-membraned vesicles.
Process:
Lysosomal membrane undergoes dynamic remodeling
Cytoplasmic material is directly internalized into the lysosomal lumen
Degradation occurs immediately within lysosomesMicroautophagy can occur at the lysosomal membrane (direct microautophagy) or at the late endosome membrane (late endosomal microautophagy). Both pathways deliver cargo directly to the lysosomal lumen without forming distinct autophagosomes [20](https://pubmed.ncbi.nlm.nih.gov/21462362/).
Types of microautophagy:
- Invagination: Membrane pushes inward, forming vesicles that detach into the lumen
- Protrusion: Lysosomal membrane extends outward, engulfing extracellular material
- Septation: Membrane partitions divide portions of cytoplasm
The molecular machinery of microautophagy involves proteins similar to those in macroautophagy, including ATG proteins and the vacuolar-type H+-ATPase (v-ATPase) for acidification. However, the requirement for the ATG conjugation system differs—some forms of microautophagy require ATG proteins while others are ATG-independent [21](https://pubmed.ncbi.nlm.nih.gov/23602568/).
Role in Neurodegeneration
Microautophagy is less well-characterized in neurodegeneration but plays important roles:
- Direct lysosomal membrane remodeling allows for rapid response to stress
- May compensate for macroautophagy defects
- LAMP2 deficiency (Danon disease) impairs microautophagy, causing cardiomyopathy and intellectual disability
- Lysosomal storage disorders show microautophagy alterations
LAMP2 deficiency causes Danon disease, a lysosomal storage disorder characterized by cardiomyopathy, myopathy, and intellectual disability. The defect in microautophagy due to LAMP2 loss leads to accumulation of autophagic material within lysosomes [22](https://pubmed.ncbi.nlm.nih.gov/21697824/).
Neurons in Danon disease show accumulation of autophagic vacuoles and cytoplasmic inclusions, demonstrating the importance of microautophagy for neuronal proteostasis. Interestingly, LAMP2 deficiency also impairs CMA, highlighting the interconnected nature of lysosomal degradation pathways [23](https://pubmed.ncbi.nlm.nih.gov/22155081/).
Key Regulators
| Protein | Function | Disease Relevance |
|---------|----------|-------------------|
| LAMP2 | Lysosomal membrane glycoprotein | Danon disease, potential in AD |
| HSP90 | Chaperone, stabilizes lysosomal proteins | Target for enhancement |
| v-ATPase | Acidification required for activity | Modulators in development |
| Cathepsins | Degradative enzymes | Activity declines with age |
| mTORC1 | Inhibits microautophagy initiation | Hyperactive in AD |
Molecular Mechanism
CMA is the most selective form of autophagy, involving the direct translocation of cytosolic proteins across the lysosomal membrane through the LAMP2A receptor complex [24](https://pubmed.ncbi.nlm.nih.gov/8662539/).
Recognition step:
- Cytosolic proteins containing a KFERQ motif are recognized by HSC70 (heat shock cognate 70 kDa protein)
- HSC70 binds the motif and targets the protein to the lysosome
- The KFERQ motif consists of a specific recognition sequence: [Q]-[F]-[E]-[R]-[K]-[V]-[L]-[I]-X-[D/E]
Translocation step:
- LAMP2A forms a multimeric translocation complex on the lysosomal membrane (typically 6-9 LAMP2A molecules)
- The substrate protein unfolds and passes through the channel
- Luminal HSC70 (also known as gapDH) assists in pulling the protein into the lumen
- Cathepsins degrade the translocated protein
CMA activity is regulated at multiple levels: LAMP2A expression, HSC70 availability, substrate modification status, and lysosomal membrane integrity [25](https://pubmed.ncbi.nlm.nih.gov/22898929/).
Key components:
- LAMP2A: Lysosomal-associated membrane protein 2A, the CMA receptor
- HSC70 (cytosolic): Identifies KFERQ motifs
- HSC70 (lysosomal/lumenal): Facilitates translocation
- Co-chaperones: HSP90, Bag1, Hsc70-interacting protein (HIP)
Role in Neurodegeneration
CMA dysfunction is increasingly recognized as a critical factor in neurodegeneration [26](https://pubmed.ncbi.nlm.nih.gov/17362839/).
Alzheimer's Disease:
- Aβ and Tau inhibit CMA
- LAMP2A expression decreases with age and in AD
- CMA degradation of phosphorylated Tau is impaired
- Loss of CMA contributes to Aβ accumulation [27](https://pubmed.ncbi.nlm.nih.gov/21296468/)
In AD, both Aβ and phosphorylated Tau directly inhibit CMA by binding to LAMP2A and disrupting the translocation complex. This creates a feedforward loop where CMA impairment leads to further accumulation of Aβ and Tau [28](https://pubmed.ncbi.nlm.nih.gov/23887132/).
Parkinson's Disease:
- α-synuclein is a CMA substrate; mutant forms fail to undergo CMA
- G2019S LRRK2 impairs CMA function
- Loss of CMA increases α-synuclein aggregation
- DJ-1 (PARK7) is a CMA substrate; mutations cause early-onset PD [29](https://pubmed.ncbi.nlm.nih.gov/21782233/)
Wild-type α-synuclein is efficiently degraded by CMA, but the A53T and A30P mutants associated with familial PD cannot be translocated and instead inhibit CMA activity, leading to broader proteostasis failure [30](https://pubmed.ncbi.nlm.nih.gov/17663982/).
Other neurodegenerative diseases:
- Huntingtin with expanded polyglutamine repeats inhibits CMA
- TDP-43 in ALS undergoes CMA
- SOD1 mutants in familial ALS show CMA impairment [31](https://pubmed.ncbi.nlm.nih.gov/21761479/)
Therapeutic Targeting
CMA represents a promising therapeutic target due to its selectivity:
| Strategy | Target | Approach |
|----------|--------|----------|
| LAMP2A enhancement | Expression increase | Gene therapy, small molecules |
| HSC70 modulation | Chaperone activity | Pharmacological enhancement |
| Substrate availability | KFERQ motif exposure | Post-translational modification |
| Lysosomal function | pH, cathepsin activity | pH modulators |
Comparative Analysis
Autophagy Type Selection in Neurons
Neurons utilize all three autophagy types, but their relative importance varies:
Basal autophagy: Predominantly CMA for routine protein turnover
Stress-induced: Macroautophagy activated during cellular stress
Organelle quality control: Mitophagy (a specialized macroautophagy) for mitochondria
Aging: All forms decline with age, contributing to neurodegenerationThe activity of all three autophagy types declines with normal aging, but the decline is particularly pronounced for CMA. LAMP2A expression decreases significantly in aged neurons, leading to accumulation of CMA substrates [32](https://pubmed.ncbi.nlm.nih.gov/22898929/).
Dysfunction Patterns in Disease
| Disease | Macroautophagy | Microautophagy | CMA |
|---------|---------------|----------------|-----|
| AD | Impaired initiation/fusion | Declined with age | Inhibited by Aβ/Tau |
| PD | LRRK2 impairs function | GBA1 affects function | α-syn fails CMA |
| ALS | TDP-43 blocks fusion | Not well studied | Inhibited by aggregates |
| Huntington's | Impaired cargo recognition | Not well studied | Inhibited by mutant HTT |
Pathway Diagram
Mermaid diagram (expand to render)
Key Proteins Summary
Macroautophagy
| Protein | Function | Therapeutic Target |
|---------|----------|-------------------|
| mTOR | Master regulator, inhibits autophagy | mTOR inhibitors (rapamycin) |
| ULK1 | Kinase initiating autophagosome formation | ULK1 activators |
| Beclin-1 | PI3K complex component | Gene therapy |
| LC3 | Autophagosome marker | ATG gene expression |
| p62 | Selective autophagy receptor | p62 modulators |
| ATG proteins | Conjugation machinery | Various |
CMA
| Protein | Function | Therapeutic Target |
|---------|----------|-------------------|
| LAMP2A | CMA receptor | Gene therapy |
| HSC70 | Chaperone, substrate recognition | Pharmacological enhancement |
| HSP90 | Co-chaperone, stabilizer | Inhibitors for activation |
| Cathepsins | Degradative enzymes | Activity modulators |
Therapeutic Implications
Current Approaches
mTOR inhibition: Promotes macroautophagy via ULK1 activation
TFEB activation: Increases expression of autophagy-lysosomal genes
CMA enhancement: LAMP2A upregulation, chaperone modulation
Lysosomal function: v-ATPase modulators, pH restorationChallenges
- Blood-brain barrier: Many compounds don't reach the CNS
- Neuronal specificity: Systemic effects may be problematic
- Age-related decline: Harder to activate autophagy in aged neurons
- Disease stage: Optimal intervention timing unclear
- Biphasic effects: Excessive autophagy can be detrimental
Future Directions
- Combination therapy: Multiple autophagy targets
- Gene therapy: AAV-mediated expression of ATG genes, TFEB, LAMP2A
- Small molecule modulators: Selective activators/inhibitors
- Biomarkers: Monitoring autophagy activity in patients
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway) - Overview of the complete pathway
- [mTOR Signaling in Neurodegeneration](/mechanisms/mtor-neurodegeneration) - Upstream regulation
- [Protein Aggregation and Misfolding](/mechanisms/protein-aggregation) - Cargo in impaired autophagy
- [Mitochondrial Dynamics](/entities/mitochondrial-dynamics) - Mitophagy and organelle quality control
- [TFEB Protein](/proteins/tfeb) - Master regulator of lysosomal biogenesis
- [MTOR Protein](/proteins/mtor-protein) - Central kinase regulator
- [Autophagy-Enhancing Therapies](/therapeutics/autophagy-enhancing-therapies) - Therapeutic strategies
See Also
- [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
- [mTOR Signaling in Neurodegeneration](/mechanisms/mtor-neurodegeneration)
- [Protein Aggregation and Misfolding](/mechanisms/protein-aggregation)
- [TFEB Protein](/proteins/tfeb)
- [MTOR Protein](/proteins/mtor-protein)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Unknown, Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/22078879/)
[Egan DF et al., Phosphorylation of ULK1 by AMPK initiates autophagy. Nature (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21465661/)
[Dunlop EA et al., ULK1 complex. Autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24270826/)
[Unknown, Burman C, Ktistakis NT. Regulation of autophagy by phosphatidylinositol 3-phosphate. FEBS Letters (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20083227/)
[Funderburk SF et al., The Beclin-VPS34 complex at the crossroads of autophagy and endocytosis. Cell Research (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/22949840/)
[Ichimura Y et al., LC3 and autophagy. Autophagy (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/23602568/)
[Hanada T et al., The ATG5-ATG12 complex. Journal of Biological Chemistry (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/12665528/)
[Tanida I et al., Autophagy basics. Microbiology and Immunology (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18246591/)
[Itakura E et al., Machinery of autophagosome-lysosome fusion. Journal of Biological Chemistry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/23445837/)
[McGhee MD et al., HOPS complex in lysosomal fusion. Developmental Cell (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25855379/)
[Unknown, Nixon RA. The role of autophagy in neurodegenerative disease. Nature Medicine (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23921753/)
[Bove J et al., Neurodegeneration in Alzheimer's disease. Seminars in Cell & Developmental Biology (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/28793252/)
[Nixon RA et al., Autophagy failure in Alzheimer disease. Nature Reviews Neuroscience (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/19151615/)
[Unknown, Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease. Neuron (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25611506/)
[Du Y et al., p62 in Parkinson's disease. Journal of Neural Transmission (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/26577373/)
[Bose JK et al., Regulation of autophagy by TDP-43 in neurodegenerative diseases. Molecular Neurobiology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21638167/)
[Bilsland LG et al., Deficits in axonal transport in ALS. Neurobiology of Aging (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/24356310/)
[Martin DD et al., Autophagy in Huntington's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25449132/)
[Li WW et al., Microautophagy: lesser-known pathway of protein degradation. Shanghai Archives of Psychiatry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22783373/)
[Sahu R et al., Microautophagy in mammalian cells. Autophagy (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21462362/)
[Mizushima N et al., ATG proteins in autophagy. Autophagy (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/23602568/)
[Nishino I et al., LAMP2 and Danon disease. Nature Reviews Neurology (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21697824/)
[Rothenberg C et al., LAMP2 deficiency and neuronal function. Autophagy (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22155081/)
[Unknown, Cuervo AM, Dice JF. A receptor for the selective uptake and degradation of proteins by lysosomes. Science (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/8662539/)
[Kiffin R et al., Regulation of chaperone-mediated autophagy. Journal of Molecular Biology (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/22898929/)
[Unknown, Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration. Lancet Neurology (2007) (2007)](https://pubmed.ncbi.nlm.nih.gov/17362839/)
[Unknown, Koga H, Cuervo AM. Chaperone-mediated autophagy dysfunction in the pathogenesis of neurodegeneration. Neurobiology of Disease (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21296468/)
[Xilouri M et al., Impairment of chaperone-mediated autophagy. Brain (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23887132/)
[Catz DF et al., DJ-1 is a CMA substrate in Parkinson's disease. Journal of Biological Chemistry (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/21782233/)
[Xilouri M et al., α-synuclein and CMA in PD. Journal of Neural Transmission (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/17663982/)
[Deng HX et al., Mutations in UBQLN2 cause ALS. Nature (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21761479/)
[Unknown, Cuervo AM, Wong E. Chaperone-mediated autophagy. Nature Reviews Molecular Cell Biology (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25469861/)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
- [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
- [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: STX17
- [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
- [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
- [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
- [Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: LAMP1
Related Analyses:
- [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Autophagy Types in Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)